Topical treatment for cutaneous leishmaniasis

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 538-544

  Garnier, Tracy ^a   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amphotericin B; Cutaneous leishmaniasis; Imiquimod; Licochalcone A; Miltefosine; Paromomycin; Topical treatments

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIPROTOZOAL AGENT; BCG VACCINE; CLOTRIMAZOLE; GAMMA INTERFERON; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; ITRACONAZOLE; KANAMYCIN; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MICONAZOLE; MILTEFOSINE; N ACETYL S NITROSOPENICILLAMINE; NEOMYCIN; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTAVALENT ANTIMONY; PH 104; PH 81; RIFAMPICIN; STIBOGLUCONATE SODIUM; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 279396; ANTITRYPANOSOMAL AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; LEISHMANIA; NONHUMAN; OINTMENT; PATIENT COMPLIANCE; PRURITUS; REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; DRUG DESIGN; INTRADERMAL DRUG ADMINISTRATION; SKIN ABSORPTION;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, CUTANEOUS; DRUG DESIGN; HUMAN; LEISHMANIASIS, CUTANEOUS; SKIN ABSORPTION; SUPPORT, NON-U.S. GOV'T; TRYPANOCIDAL AGENTS; HUMANS;

EID: 0036527053     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Epidemiology of cutaneous leishmaniasis
2. The increase in risk factors for leishmaniasis worldwide
3. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L (V) guyanensis in Brazil: Clinical findings and diagnostic approach
4. Cutaneous leishmaniasis: Clinical aspect
5. Histologic diagnosis of cutaneous leishmaniasis
6. Cutaneous leishmaniasis
7. Immune response to Leishmania infection in human skin
8. Cutaneous leishmaniasis. The parasite
9. The leishmaniases as emerging and reemerging zoonoses
10. Cutaneous leishmaniasis: Clinical features and diagnosis
11. Monitoring drug resistance in leishmaniasis
12. Global control and Leishmania HIV co-infection
13. Leishmania and human immunodeficiency virus coinfection: The first 10 years
14. AIDS and the skin: Parasitic diseases
15. Treatment of cutaneous leishmaniasis (Old World)
16. Treatment of New World cutaneous and mucosal leishmaniases
17. Leishmaniasis
18. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony
19. Treatment of cutaneous leishmaniasis with antimony: Intramuscular versus intralesional administration
20. Management of cutaneous leishmaniasis
21. Practical progress and new drugs for changing patterns of leishmaniasis
22. Treatment of cutaneous leishmaniasis: Retrospectives and advances for the 21st century
23. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent
24. Itraconazole and leishmaniasis: A randomised double-blind trial in cutaneous disease
25. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study
26. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey
27. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major
28. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
29. Topical chemotherapy of cutaneous leishmaniasis
30. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals
31. Leishmania major: Antileishmanial activity of methylbenzethonium chloride
32. Topical treatment of cutaneous leishmaniasis
33. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study
34. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala
35. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: A clinical study under field conditions in Ecuador
36. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study
37. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis
38. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: Results of an open study in London
39. A randomized, placebo-controlled trial in Tunisia treated cutaneous leishmaniasis with paromomycin ointment
40. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran
41. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin
42. Studies on the topical treatment of experimental cutaneous leishmaniasis: The therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin
43. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin
44. New approaches to cutaneous treatment in Latin America
45. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
46. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis
47. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome
48. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B
49. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B
50. The activities of four anticancer alkyllysophospholipids against Leishmania donavani, Trypanosoma cruzi and Trypanosoma brucei
51. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
52. Miltefosine in recurrent cutaneous breast cancer
53. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis
54. Treatment of cutaneous leishmaniasis with nitric-oxide donor
55. A topical nitric oxide-generating therapy for cutaneous leishmaniasis
56. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action
57. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator
58. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia
59. Effects of itraconazole and terbinafine on Leishmania major lesions in BALB/c mice
60. Failure of chlorpromazine or amitriptyline ointments to influence the course of experimental cutaneous leishmaniasis
61. The activity of plumbagin and other electron carriers against Leishmania donovani and Leishmania mexicana amazonensis
62. Antileishmanial effects of clofazimine and other antimycobacterial agents
63. Herbicides to curb human parasitic infections: In vitro and in vivo effects of trifluralin on the trypanosomatid protozoans
64. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani
65. Antileishmanial activity of novel oxygenated chalcones
66. The relationship between structure and barrier function of skin
67. The determination of a diffusional pathlength through the stratum corneum
68. Effects of iontophoresis and electroporation on the stratum corneum. Review of the biophysical studies
69. Transdermal drug delivery: Overcoming the skin's barrier function
70. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations
71. The selection and design of topical and transdermal agents: A review
72. Skin, the final frontier
73. Dermal metabolism
74. Dermal metabolism of topically applied drugs: Pathways and models reconsidered
75. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery
76. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac
77. Distribution of parasite cysteine proteinases in lesions of mice infected with Leishmania mexicana amastigotes
78. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target